Epizyme scores important follicular lymphoma approval with TazverikEpizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in Share XEpizyme scores important follicular lymphoma approval with Tazverikhttps://pharmaphorum.com/news/epizyme-unlocks-more-sales-with-tazverik-follicular-lymphoma-approval/
FDA approves Epizyme’s Tazverik in sarcomaThe US regulator has approved Epizyme’s Tazverik (tazemetostat) for advanced sarcoma, providing a new option for a disease Share XFDA approves Epizyme’s Tazverik in sarcomahttps://pharmaphorum.com/news/fda-approves-epizymes-tazverik-in-sarcoma/
4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWEREDDrug Discovery Conference Share X4 KEY QUESTIONS IN NEW EXPERIMENTAL TECHNOLOGIES ANSWEREDhttps://pharmaphorum.com/partner-content/4-key-questions-in-new-experimental-technologies-answered/